VSV-hIFNbeta-NIS With or Without Ruxolitinib Phosphate in Treating Patients With Stage IV or Recurrent Endometrial Cancer
Status:
Recruiting
Trial end date:
2023-07-15
Target enrollment:
Participant gender:
Summary
This phase I trial studies the side effects and best dose of vesicular stomatitis virus-human
interferon beta-sodium iodide symporter (VSV-hIFNbeta-NIS) with or without ruxolitinib
phosphate in treating patients with stage IV endometrial cancer or endometrial cancer that
has come back. The study virus, VSV-hIFNbeta-NIS, has been changed so that it has restricted
ability to spread to tumor cells and not to healthy cells. It also contains a gene for a
protein, NIS, which helps the body concentrate iodine making it possible to track where the
virus goes. VSV-hIFNbeta-NIS may be able to kill tumor cells without damaging normal cells.
Ruxolitinib phosphate may stop the growth of tumor cells by blocking some of the enzymes
needed for cell growth. Giving VSV-hIFNbeta-NIS with ruxolitinib phosphate may work better in
treating patients with endometrial cancer compared to VSV-hIFNbeta-NIS alone.